The International Agency for Research on Cancer classified talc as “probably carcinogenic to humans” based on limited human evidence, sufficient animal evidence, and strong mechanistic data, drawing a ...

More than 1,300 Victorians have joined a class action against Johnson & Johnson alleging its talcum powder products left them with ovarian cancer, mesothelioma (cancer affecting the lungs), and other ...

Opinion: Judges must enforce the rigorous scrutiny that Federal Rule of Evidence 702 requires, particularly when scientific evidence is mixed or fragile.

In this monthly roundup, legal disputes and regulatory challenges underscore the growing complexity of operating in the global beauty and personal care industry. From trademark battles and counterfeit ...

Dean Omar Branham & Shirley, the Dallas plaintiffs' firm that won verdicts of $966 million and $1.5 billion last year, is spearheading both mesothelioma trials that are set to begin in the coming days ...

Lawyers nationwide are gearing up for bellwether ovarian cancer trials against Johnson & Johnson this year, but a plaintiff ...

Two mesothelioma trials, one in Washington and one in Florida, kick off against Johnson & Johnson. A high-stakes trial tees off involving four premature babies who developed a gastrointestinal illness ...

Across Talc, Depo-Provera, and Cartiva litigation, Legal Bay continues to provide pre-settlement funding, post-verdict funding, and, where applicable, appellate funding solutions. Mass tort and ...

Johnson & Johnson (NYSE:JNJ) was found liable by a Philadelphia jury in an ovarian cancer case linked to long term use of its talc based baby powder. The jury awarded compensatory and punitive damages ...

Waters Kraus Paul & Siegel law firm: Mesothelioma cancer death linked to company's asbestos-contaminated talc cosmetics ...

Johnson & Johnson's third attempt to use bankruptcy proceedings to settle lawsuits claiming that its talc-based products harmed consumers has been rejected. In a Houston, Texas court, Judge ...

Tam Ha does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...